Literature DB >> 18580877

COMT Val108/158Met polymorphism and the modulation of task-oriented behavior in children with ADHD.

Sarojini Sengupta1, Natalie Grizenko, Norbert Schmitz, George Schwartz, Johanne Bellingham, Anna Polotskaia, Marina Ter Stepanian, Yukiori Goto, Anthony A Grace, Ridha Joober.   

Abstract

It has been suggested that the symptoms of attention-deficit/hyperactivity disorder (ADHD), including inattention and/or hyperactivity/impulsivity, translate into deficits in task-oriented behavior or problem-focused activity. The frontosubcortical dopamine pathway has been implicated in ADHD. One of the key modulators of extracellular dopamine levels in the prefrontal cortex is catechol-O-methyltransferase (COMT). The objective of this study was to examine the association of the COMT Val(108/158)Met polymorphism with (1) task-oriented behavior in children with ADHD, and (2) response of this behavior given methylphenidate (MPH) treatment. Children of Caucasian ethnicity, having ADHD (n=188), were assessed using the Restricted Academic Situation Scale (RASS). The RASS uses a simulated academic environment within the research clinic, to assess the child's ability for independent, sustained orientation to an assignment of math problems. Each child was administered placebo and MPH (0.5 mg/kg in a divided b.i.d. dose), each for a 1-week period, in a randomized, double-blind, crossover trial. On day 3 of the respective treatment week, the child was administered placebo/MPH in the clinic, and the acute change in behavior (before and 1 h after treatment) was evaluated on the RASS. Analysis was carried out using mixed model analysis of variance. Significant main effects of COMT genotype (F(2,184)=5.12, p=0.007) and treatment (F(1,184)=44.26, p<0.001) on task-oriented behavior were observed. However, no genotype by treatment interaction was observed. These results suggest that the COMT Val(108/158)Met polymorphism modulates task-oriented behavior, but it does not modulate the response of this behavior with MPH treatment.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18580877      PMCID: PMC2885152          DOI: 10.1038/npp.2008.85

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  45 in total

1.  Methylphenidate preferentially increases catecholamine neurotransmission within the prefrontal cortex at low doses that enhance cognitive function.

Authors:  Craig W Berridge; David M Devilbiss; Matthew E Andrzejewski; Amy F T Arnsten; Ann E Kelley; Brooke Schmeichel; Christina Hamilton; Robert C Spencer
Journal:  Biol Psychiatry       Date:  2006-06-23       Impact factor: 13.382

2.  Catechol-o-methyltransferase enzyme activity and protein expression in human prefrontal cortex across the postnatal lifespan.

Authors:  E M Tunbridge; C S Weickert; J E Kleinman; M M Herman; J Chen; B S Kolachana; P J Harrison; D R Weinberger
Journal:  Cereb Cortex       Date:  2006-07-11       Impact factor: 5.357

3.  Linkage study of catechol-O-methyltransferase and attention-deficit hyperactivity disorder.

Authors:  C L Barr; K Wigg; M Malone; R Schachar; R Tannock; W Roberts; J L Kennedy
Journal:  Am J Med Genet       Date:  1999-12-15

4.  Impact of complex genetic variation in COMT on human brain function.

Authors:  A Meyer-Lindenberg; T Nichols; J H Callicott; J Ding; B Kolachana; J Buckholtz; V S Mattay; M Egan; D R Weinberger
Journal:  Mol Psychiatry       Date:  2006-06-20       Impact factor: 15.992

5.  Dopamine-mediated stabilization of delay-period activity in a network model of prefrontal cortex.

Authors:  D Durstewitz; J K Seamans; T J Sejnowski
Journal:  J Neurophysiol       Date:  2000-03       Impact factor: 2.714

Review 6.  Stimulants: Therapeutic actions in ADHD.

Authors:  Amy F T Arnsten
Journal:  Neuropsychopharmacology       Date:  2006-07-19       Impact factor: 7.853

7.  No association between catechol-O-methyltransferase (COMT) gene polymorphism and attention deficit hyperactivity disorder (ADHD) in an Irish sample.

Authors:  Z Hawi; N Millar; G Daly; M Fitzgerald; M Gill
Journal:  Am J Med Genet       Date:  2000-06-12

8.  No association between low- and high-activity catecholamine-methyl-transferase (COMT) and attention deficit hyperactivity disorder (ADHD) in a sample of Turkish children.

Authors:  E Tahir; S Curran; Y Yazgan; F Ozbay; B Cirakoglu; P J Asherson
Journal:  Am J Med Genet       Date:  2000-06-12

9.  Failure to replicate an association between the catechol-O-methyltransferase polymorphism and attention deficit hyperactivity disorder in a second, independently recruited Israeli cohort.

Authors:  I Manor; M Kotler; Y Sever; J Eisenberg; H Cohen; R P Ebstein; S Tyano
Journal:  Am J Med Genet       Date:  2000-12-04

Review 10.  The catechol-O-methyl transferase (COMT) gene as a candidate for psychiatric phenotypes: evidence and lessons.

Authors:  N Craddock; M J Owen; M C O'Donovan
Journal:  Mol Psychiatry       Date:  2006-05       Impact factor: 15.992

View more
  15 in total

Review 1.  Cognitive effects of nicotine: genetic moderators.

Authors:  Aryeh I Herman; Mehmet Sofuoglu
Journal:  Addict Biol       Date:  2010-04-29       Impact factor: 4.280

2.  COMT Val158Met genotype as a risk factor for problem behaviors in youth.

Authors:  Matthew D Albaugh; Valerie S Harder; Robert R Althoff; David C Rettew; Erik A Ehli; Timea Lengyel-Nelson; Gareth E Davies; Lynsay Ayer; Julie Sulman; Catherine Stanger; James J Hudziak
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2010-07-01       Impact factor: 8.829

Review 3.  Sleep apnea in pediatric neurological conditions.

Authors:  Gabor Szuhay; Josh Rotenberg
Journal:  Curr Neurol Neurosci Rep       Date:  2009-03       Impact factor: 5.081

4.  Placebo response and its determinants in children with ADHD across multiple observers and settings: A randomized clinical trial.

Authors:  Weam Fageera; Alexandru Traicu; Sarojini M Sengupta; Marie-Eve Fortier; Zia Choudhry; Aurélie Labbe; Natalie Grizenko; Ridha Joober
Journal:  Int J Methods Psychiatr Res       Date:  2017-06-30       Impact factor: 4.035

5.  Genetic evidence for the association of the hypothalamic-pituitary-adrenal (HPA) axis with ADHD and methylphenidate treatment response.

Authors:  Marie-Ève Fortier; Sarojini M Sengupta; Natalie Grizenko; Zia Choudhry; Geeta Thakur; Ridha Joober
Journal:  Neuromolecular Med       Date:  2012-10-10       Impact factor: 3.843

6.  PharmGKB summary: methylphenidate pathway, pharmacokinetics/pharmacodynamics.

Authors:  Tyler Stevens; Katrin Sangkuhl; Jacob T Brown; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2019-08       Impact factor: 2.089

Review 7.  Psychopathological aspects of dopaminergic gene polymorphisms in adolescence and young adulthood.

Authors:  Zsofia Nemoda; Anna Szekely; Maria Sasvari-Szekely
Journal:  Neurosci Biobehav Rev       Date:  2011-04-15       Impact factor: 8.989

Review 8.  Molecular genetics of attention-deficit/hyperactivity disorder: an overview.

Authors:  Tobias Banaschewski; Katja Becker; Susann Scherag; Barbara Franke; David Coghill
Journal:  Eur Child Adolesc Psychiatry       Date:  2010-02-10       Impact factor: 4.785

9.  Low enzymatic activity haplotypes of the human catechol-O-methyltransferase gene: enrichment for marker SNPs.

Authors:  Andrea G Nackley; Svetlana A Shabalina; Jason E Lambert; Mathew S Conrad; Dustin G Gibson; Alexey N Spiridonov; Sarah K Satterfield; Luda Diatchenko
Journal:  PLoS One       Date:  2009-04-13       Impact factor: 3.240

Review 10.  Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD).

Authors:  Ole Jakob Storebø; Erica Ramstad; Helle B Krogh; Trine Danvad Nilausen; Maria Skoog; Mathilde Holmskov; Susanne Rosendal; Camilla Groth; Frederik L Magnusson; Carlos R Moreira-Maia; Donna Gillies; Kirsten Buch Rasmussen; Dorothy Gauci; Morris Zwi; Richard Kirubakaran; Bente Forsbøl; Erik Simonsen; Christian Gluud
Journal:  Cochrane Database Syst Rev       Date:  2015-11-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.